 | | Frequently Asked Questions |
General Inquiries
| What is my cost basis for Caremark? | | Caremark
|
| What happens to the payment rights that Somatogen shareholders received as part of the acquisition by Baxter of Somatogen in 1998?
| | Payments on the contingent payment rights are due generally upon commercial sales made prior to March 15, 2008 of products that used the recombinant hemoglobin technology acquired from Somatogen. Given Baxter's decision to discontinue its investment in its Phase I recombinant hemoglobin therapeutic product, it is unlikely that any payments will be made. Please refer to your specific contingent payment rights certificates for further details. |
| What has happened with Baxter's dividend policy? | | In November 2006, Baxter announced that beginning in 2007 and subject to further board action, the company anticipates changing the dividend payment schedule from its current annual dividend of $0.582 per share of Baxter common stock to a quarterly dividend targeted at a rate of $0.15 per share, which on an annual basis represents a 3 percent increase over the current annual dividend rate. The first quarterly payment is expected in the second quarter of 2007. |
| Will I still receive a dividend payment if I sell my Baxter shares prior to the January 2007 payment date?
| | You must have been a shareholder of record as of the record date in order to receive the January 2007 dividend payment. The record date was December 8, 2006. If you were not a shareholder of record as of the December record date, you will not receive the January 2007 dividend payment. |
| If I sold my Baxter shares prior to the record date, will I receive a prorated amount of the annual dividend payment? | | No. You must be a shareholder of record as of the record date in order to receive the January 2007 dividend payment. |
| Where is Baxter traded?
| | Baxter common stock is listed as BAX on the New York, Chicago and Swiss Exchanges. The New York Stock Exchange is the principal market on which the company's common stock is traded |
| Why were there two Baxter listings on the NYSE? | | Currently, Baxter’s only security trading on the NYSE is our common stock; symbol BAX. There has been no change to the nature or status of that security. The listing symbol BAX_P represented the Equity Units that were issued by Baxter in December of 2002. The Equity Units were delisted from the NYSE on February 16, 2006 as a result of the settlement as of such date of the purchase contract component of the Equity Units. The purchase contract component entitled holders of Equity Units to receive shares of Baxter common stock on a fixed date for an agreed upon price. For more information about the Equity Units, please see the final prospectus filed with the U.S. SEC. |
| What was the conversion rate for the Baxter Equity Units? | | For each Equity Unit you would have received 1.4011 shares of Baxter common stock on February 16, 2006. |
| Who is Baxter’s transfer agent? | | Baxter’s transfer agent is: Computershare P.O. Box 43069 Providence, RI 02940-3069, Telephone: (888) 359-8645 or (201) 324-0498; Internet: www.computershare.com
|
| What is Baxter’s CUSIP? | Baxter’s CUSIP for the common stock is 071813109.
|
| Does Baxter have a Dividend Reinvestment Policy? | | Baxter does offer an automatic dividend reinvestment program to all holders of Baxter International Inc. common stock. Additional information is available upon request from: Computershare P.O. Box 43069 Providence, RI 02940-3069; Telephone: (888) 359-8645 or (201) 324-0498; Internet: www.computershare.com. |
| |